as is the infrastructure to maintain and follow up on such consents. Thus, many archival specimens would be ineligible for use in research unless patients were contacted for an additional consent for this purpose. Such recontact is usually unsuccessful, as many patients move in and out of hospital systems. Recontact may also be perceived as intrusive and an unwarranted invasion of privacy.
Currently, most translational research using archival collections is performed without problems based on a waiver of consent by the local IRBs. If this were no longer permitted except in very rare circumstances, translational research would be crippled and many advances in medical care would be delayed. This proposal would also reduce research studies focused on minorities, increase racial disparities, and introduce biases into research because only selected patients will be studied. Many hospitals, especially smaller community hospitals, will not likely have the resources to implement consent for all biospecimens collected during the course of routine care. Thus, important retrospective studies involving underserved populations seen at these hospitals could not be conducted, and these populations would be excluded from these studies. (An example is presented after my recommendations.)
The ethics of this proposal are also of concern. As illustrated below, the proposal will, except in rare cases, inhibit the use of many archival specimens for retrospective research studies. Hence, there is almost a complete emphasis in the proposed modified Common Rule on patient autonomy, with little consideration of the social value and benefit of this kind of research or issues relating to justice. This will result in a great decrease both in research and in improvements in medical care, leading to missed opportunities and lost lives caused by delays in the development of new responses to therapy, therapeutic approaches, and other research affecting medical care.
Many of these same concerns were addressed in the comments submitted in response to the previously proposed rules in the Advanced Notice of Proposed Rulemaking by the Secretary's (i.e., Health and Human Services) own Advisory Committee on Human Research Protection (SACHRP; ref. 1). Unfortunately, many of the same problems remain and this proposal will have the same serious adverse consequences envisioned in the prior comments.
It is important to note that two alternative proposals are presented in the NPRM. "Alternative Proposal A" requires consent only for all whole-genome sequencing studies. Of the alternative proposals presented, Proposal A, although not an optimal solution, should be considered because this choice will reduce the impact of the proposed changes on research and more closely balance autonomy with beneficence.
In conclusion, I believe that the primary proposals related to biospecimen research in the NPRM will not, in fact, accomplish one of the stated goals of this NPRM to "facilitate cutting edge research in genomics and other 'omics' such as the transcriptome and the microbiome, which generate a wealth of data from biospecimens designed to inform the development of treatments and preventative measures for chronic diseases such as cancer." Furthermore, in my view, it does not appropriately balance the principles of autonomy, beneficence, and justice for the use of archival specimens collected during the course of routine care and will lead to missed opportunities and lost lives due to delays in important research.
Given the potential importance of the proposed changes, I encourage readers to review what is being proposed in the NPRM (2) and to submit comments, identified by docket ID number HHS-OPHS-2015-0008, by the December 7, 2015, deadline in one of the following ways: Input from ALL stakeholders, especially individual investigators, in addition to associated scientific organizations, is necessary to ensure that important research can proceed using archived human specimens, while at the same time protecting the rights and welfare of research participants. This input should include examples from researchers of how the proposed changes would affect future use of archived specimens. Individuals who wish to provide feedback should consider the following approach:
(1) The waiver of informed consent by IRBs should continue to be permitted for archival tissues using the waiver criteria in the current Common Rule.
(2) If this is unacceptable, of those alternative proposals suggested in the NPRM, Alternative Proposal A should be utilized.
The following example demonstrates the potential impact on retrospective studies involving pathology specimens:
A researcher wants to use residual prostate cancer specimens from the pathology archives from a small community hospital that were collected 5 years after the compliance date for an important study to look at new markers of response to therapy in African-American prostate cancer patients. However, the hospital did not envision this research at the time the pathology specimens were collected. Furthermore, the hospital did not have sufficient resources to implement a process to obtain consent for the research use of all residual specimens collected during the course of routine care at that hospital. The research will answer an important research question about the response to therapy in African-American patients. It would not be possible to seek consent from all patients whose pathology biospecimens would be studied, as many patients move out of the hospital system and/or cannot be located.
In spite of these constraints, we do not think that this research would meet the criteria for a waiver under the new waiver criteria for biospecimens proposed in the NPRM because a new study could be initiated prospectively if sufficient resources were available. The retrospective research study would not be permissible, even though the biospecimens could be evaluated in a de-identified way, with few risks to study subjects. A new prospective study would have to be initiated to obtain consent from patients and collect new biospecimens, and patients would need to be followed for many years to obtain the required outcome data. This would inconvenience and put at some minimal risk the new patient populations being studied, and would be costly and wasteful of existing resources when the necessary specimens and follow-up data already exist. Perhaps most importantly, because time would be required in a new prospective study to accrue the follow-up data (sometimes 5-10 years) delays in translating important research to the bedside would result (e.g., new markers of response to therapies), in turn resulting in lost lives, as well as missed opportunities to improve medical care. In addition, important patient populations would be excluded from research. This is not only an issue of justice, but could lead to harm to patients if results from research studies are not generalizable to all populations.
Although this example focuses on small community hospitals, implementing consent for all biospecimens collected by a hospital may be challenging at even well-resourced hospitals, hampering retrospective studies on archived biospecimens and requiring new prospective studies to be initiated.
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